Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash & Current Investments (2017 - 2026)

Inspire Medical Systems' Cash & Current Investments history spans 10 years, with the latest figure at $283.8 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments fell 23.12% to $283.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $283.8 million, a 23.12% decrease, with the full-year FY2025 number at $308.3 million, down 30.81% from a year prior.
  • Cash & Current Investments hit $283.8 million in Q1 2026 for Inspire Medical Systems, down from $308.3 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for INSP hit a ceiling of $467.1 million in Q2 2023 and a floor of $196.3 million in Q2 2022.
  • Historically, Cash & Current Investments has averaged $379.1 million across 5 years, with a median of $427.5 million in 2022.
  • Biggest five-year swings in Cash & Current Investments: surged 137.9% in 2023 and later plummeted 31.56% in 2025.
  • Tracing INSP's Cash & Current Investments over 5 years: stood at $451.4 million in 2022, then increased by 1.99% to $460.4 million in 2023, then fell by 3.22% to $445.5 million in 2024, then plummeted by 30.81% to $308.3 million in 2025, then fell by 7.93% to $283.8 million in 2026.
  • Business Quant data shows Cash & Current Investments for INSP at $283.8 million in Q1 2026, $308.3 million in Q4 2025, and $322.6 million in Q3 2025.